Summary
HRSA has announced a revised 340B Rebate Model Pilot Program that could change how participating covered entities receive 340B pricing on certain drugs. Our 340B Experts can help your organization evaluate what each potential model could mean for your program and prepare for what comes next.
The 340B landscape is changing again.
HRSA has announced a revised 340B Rebate Model Pilot Program that could change how participating covered entities receive 340B pricing on certain drugs. Instead of receiving the 340B discount upfront, covered entities affected by an approved manufacturer plan would purchase selected drugs at a higher upfront price and receive the 340B benefit later through a rebate after eligible claims are validated. The revised pilot is scheduled to take effect January 1, 2027, for approved manufacturer plans and applicable selected drugs.
For 340B leaders, however, the pilot is only part of the story. Congress is simultaneously considering different approaches that could significantly alter or replace the rebate model.
In other words: three proposals, three different paths.
What Is the Revised 340B Rebate Model Pilot Program?
HRSA describes the pilot as a way to improve claims-level transparency, verify eligible 340B transactions, prevent duplicate discounts, and generate better data for future oversight and policymaking. Participation is voluntary for qualifying manufacturers, but once HRSA approves a manufacturer’s plan, covered entities acquiring affected drugs from that manufacturer would be subject to the approved rebate process.
The operational implications deserve attention. Covered entities may need to prepare for changes involving cash flow, purchasing, claims submission, data exchange, rebate reconciliation, Medicaid billing, and compliance monitoring. HRSA’s Federal Register notice itself acknowledges covered entity concerns about working capital and administrative burden.
The timeline is also moving quickly. Manufacturer applications were due August 24, 2026, with HRSA approvals, if any, expected by September 24 and implementation beginning January 1, 2027. Approved plans must provide covered entities at least 90 calendar days’ notice.
Three Proposals Could Shape What Comes Next
While covered entities prepare for HRSA’s pilot, three legislative approaches point toward very different futures for the 340B Discount Drug Program.
Path 1: SUSTAIN 340B Act — Move Toward a Clearinghouse
The bipartisan Senate SUSTAIN 340B Act would end a 340B rebate model program within one year and transition HHS toward a national claims clearinghouse. It would also clarify that 340B discounts are provided at the point of purchase rather than through rebates.
Why it matters: The focus would shift away from waiting for rebates and toward how claims are validated, data is exchanged, and discounts are delivered. That could preserve upfront pricing while creating new data and infrastructure requirements. This is the “clearinghouse” path identified in Ravin’s policy comparison.
Path 2: SECURE 340B Act — Pause Rebates While Infrastructure Develops
The House SECURE 340B Act takes a different approach. It would require manufacturers to provide the 340B ceiling price as a purchase-price reduction, not a retrospective rebate for a four-year period while a 340B data clearinghouse framework develops.
Why it matters: Covered entities would gain near-term protection from a rebate transition, although longer-term operations could still move toward a clearinghouse-based structure.
Path 3: Cassidy Discussion Draft — Multiple Discount Models
A Senate HELP Committee discussion draft from Chairman Bill Cassidy takes yet another approach. Ravin Consultants’ policy analysis summarizes this path as allowing manufacturers to choose among an upfront discount, a rebate, or an HHS-operated claims repository, with provider choice potentially available when 340B savings are passed directly to patients. The discussion draft is part of a broader proposed restructuring of the 340B Program focused on transparency, oversight, and patient benefit.
Why it matters: Of the three approaches, this could create the greatest operational variability. Covered entities may need processes that support different discount mechanisms while also documenting patient savings requirements.
What Should Covered Entities Do Now?
The policy direction is unsettled. Preparation should not be.
Covered entities should begin testing how a rebate model or an eventual clearinghouse model could affect their claims workflows, cash position, pharmacy operations, compliance controls, data exchange, and 340B savings. The transition from dispense to qualified claim deserves particular attention: under HRSA’s framework, manufacturer plans must provide at least 45 calendar days from the date of dispense for data submission, and incomplete submissions can delay the rebate process.
Finance, pharmacy, compliance, IT, and 340B Program Management teams should be working together now rather than waiting until implementation details arrive.
Turn 340B Policy Change Into an Operating Plan
Whether the future is rebates, a national clearinghouse, manufacturer choice—or another policy adjustment—the operational question remains the same:
Is your 340B Program ready to adapt without compromising compliance, cash flow, or patient impact?
Ravin Consultants helps covered entities translate 340B policy into practical action through readiness assessments, workflow design, 340B Compliance strategy, financial analysis, and implementation support. Our 340B Experts can help your organization evaluate what each potential model could mean for your program and prepare for what comes next.
Policy may change. Your preparation shouldn’t wait.